BioAtla annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
BioAtla Stock-Based Compensation Growth & History (BCAB)
BioAtla's stock-based compensation was $5.4M for fiscal 2025.
View full BioAtla company overviewBioAtla annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.4M | −$3.5M | −39.09% |
| 2024 | 2024-12-31 | $8.9M | −$4.6M | −34.13% |
| 2023 | 2023-12-31 | $13.5M | −$1.0M | −7.00% |
| 2022 | 2022-12-31 | $14.6M | −$10.6M | −42.02% |
| 2021 | 2021-12-31 | $25.1M | $22.1M | +731.14% |
| 2020 | 2020-12-31 | $3.0M | $3.0M | — |
| 2019 | 2019-12-31 | $0 | — | — |
BioAtla quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $619,000 | −$758,000 | −55.05% |
| Q1 2026 | 2026-03-31 | $956,000 | −$689,000 | −41.88% |
| Q4 2025 | 2025-12-31 | $1.1M | −$811,000 | −42.00% |
| Q3 2025 | 2025-09-30 | $1.3M | −$902,000 | −41.11% |
| Q2 2025 | 2025-06-30 | $1.4M | −$1.1M | −44.83% |
| Q1 2025 | 2025-03-31 | $1.6M | −$655,000 | −28.48% |
| Q4 2024 | 2024-12-31 | $1.9M | −$807,000 | −29.47% |
| Q3 2024 | 2024-09-30 | $2.2M | −$1.3M | −37.62% |
| Q2 2024 | 2024-06-30 | $2.5M | −$1.2M | −32.08% |
| Q1 2024 | 2024-03-31 | $2.3M | −$1.3M | −36.36% |
| Q4 2023 | 2023-12-31 | $2.7M | −$763,000 | −21.79% |
| Q3 2023 | 2023-09-30 | $3.5M | −$71,000 | −1.98% |
| Q2 2023 | 2023-06-30 | $3.7M | −$167,000 | −4.35% |
| Q1 2023 | 2023-03-31 | $3.6M | −$18,000 | −0.50% |
| Q4 2022 | 2022-12-31 | $3.5M | −$309,000 | −8.11% |
| Q3 2022 | 2022-09-30 | $3.6M | −$778,000 | −17.82% |
| Q2 2022 | 2022-06-30 | $3.8M | −$8.5M | −68.76% |
| Q1 2022 | 2022-03-31 | $3.6M | −$1.0M | −21.77% |
| Q4 2021 | 2021-12-31 | $3.8M | $788,000 | +26.08% |
| Q3 2021 | 2021-09-30 | $4.4M | $4.4M | — |
| Q2 2021 | 2021-06-30 | $12.3M | $12.3M | — |
| Q1 2021 | 2021-03-31 | $4.6M | $4.6M | — |
| Q4 2020 | 2020-12-31 | $3.0M | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
BioAtla stock-based compensation trends
Over the last five fiscal years, BioAtla's stock-based compensation increased from $3.0M to $5.4M, a change of $2.4M. The latest reported quarter, Q2 2026, shows $619,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioAtla source filings ↗